Cargando…

A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer

Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-small cell lung cancer (NSCLC), which constitutes the majority of lung cancers, is significantly more responsive to early-stage interventions. However, the early stages are often asymptomatic, and curr...

Descripción completa

Detalles Bibliográficos
Autores principales: Seneviratne, Chamindi, Shetty, Amol Carl, Geng, Xinyan, McCracken, Carrie, Cornell, Jessica, Mullins, Kristin, Jiang, Feng, Stass, Sanford
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776862/
https://www.ncbi.nlm.nih.gov/pubmed/36552904
http://dx.doi.org/10.3390/diagnostics12122897
_version_ 1784855963117813760
author Seneviratne, Chamindi
Shetty, Amol Carl
Geng, Xinyan
McCracken, Carrie
Cornell, Jessica
Mullins, Kristin
Jiang, Feng
Stass, Sanford
author_facet Seneviratne, Chamindi
Shetty, Amol Carl
Geng, Xinyan
McCracken, Carrie
Cornell, Jessica
Mullins, Kristin
Jiang, Feng
Stass, Sanford
author_sort Seneviratne, Chamindi
collection PubMed
description Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-small cell lung cancer (NSCLC), which constitutes the majority of lung cancers, is significantly more responsive to early-stage interventions. However, the early stages are often asymptomatic, and current diagnostic methods are limited in their precision and safety. The cell-free RNAs (cfRNAs) circulating in plasma (liquid biopsies) offer a non-invasive detection of spatial and temporal changes occurring in primary tumors since the early stages. To address gaps in the current cfRNA knowledge base, we conducted a pilot study for the comprehensive analysis of transcriptome-wide changes in plasma cfRNA in NSCLC patients. Total cfRNA was extracted from archived plasma collected from NSCLC patients (N = 12), cancer-free former smokers (N = 12), and non-smoking healthy volunteers (N = 12). Plasma cfRNA expression levels were quantified by using a tagmentation-based library preparation and sequencing. The comparisons of cfRNA expression levels between patients and the two control groups revealed a total of 2357 differentially expressed cfRNAs enriched in 123 pathways. Of these, 251 transcripts were previously reported in primary NSCLCs. A small subset of genes (N = 5) was validated in an independent sample (N = 50) using qRT-PCR. Our study provides a framework for developing blood-based assays for the early detection of NSCLC and warrants further validation.
format Online
Article
Text
id pubmed-9776862
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97768622022-12-23 A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer Seneviratne, Chamindi Shetty, Amol Carl Geng, Xinyan McCracken, Carrie Cornell, Jessica Mullins, Kristin Jiang, Feng Stass, Sanford Diagnostics (Basel) Article Lung cancers are the leading cause of cancer-related deaths worldwide. Studies have shown that non-small cell lung cancer (NSCLC), which constitutes the majority of lung cancers, is significantly more responsive to early-stage interventions. However, the early stages are often asymptomatic, and current diagnostic methods are limited in their precision and safety. The cell-free RNAs (cfRNAs) circulating in plasma (liquid biopsies) offer a non-invasive detection of spatial and temporal changes occurring in primary tumors since the early stages. To address gaps in the current cfRNA knowledge base, we conducted a pilot study for the comprehensive analysis of transcriptome-wide changes in plasma cfRNA in NSCLC patients. Total cfRNA was extracted from archived plasma collected from NSCLC patients (N = 12), cancer-free former smokers (N = 12), and non-smoking healthy volunteers (N = 12). Plasma cfRNA expression levels were quantified by using a tagmentation-based library preparation and sequencing. The comparisons of cfRNA expression levels between patients and the two control groups revealed a total of 2357 differentially expressed cfRNAs enriched in 123 pathways. Of these, 251 transcripts were previously reported in primary NSCLCs. A small subset of genes (N = 5) was validated in an independent sample (N = 50) using qRT-PCR. Our study provides a framework for developing blood-based assays for the early detection of NSCLC and warrants further validation. MDPI 2022-11-22 /pmc/articles/PMC9776862/ /pubmed/36552904 http://dx.doi.org/10.3390/diagnostics12122897 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Seneviratne, Chamindi
Shetty, Amol Carl
Geng, Xinyan
McCracken, Carrie
Cornell, Jessica
Mullins, Kristin
Jiang, Feng
Stass, Sanford
A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer
title A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer
title_full A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer
title_fullStr A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer
title_full_unstemmed A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer
title_short A Pilot Analysis of Circulating cfRNA Transcripts for the Detection of Lung Cancer
title_sort pilot analysis of circulating cfrna transcripts for the detection of lung cancer
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9776862/
https://www.ncbi.nlm.nih.gov/pubmed/36552904
http://dx.doi.org/10.3390/diagnostics12122897
work_keys_str_mv AT seneviratnechamindi apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT shettyamolcarl apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT gengxinyan apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT mccrackencarrie apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT cornelljessica apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT mullinskristin apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT jiangfeng apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT stasssanford apilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT seneviratnechamindi pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT shettyamolcarl pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT gengxinyan pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT mccrackencarrie pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT cornelljessica pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT mullinskristin pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT jiangfeng pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer
AT stasssanford pilotanalysisofcirculatingcfrnatranscriptsforthedetectionoflungcancer